Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 18 of 18 entries
View as:

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03709316 Org: User:
Start: 06/30/18 End: 12/30/23 Due: 12/30/24

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04178460 Org: User:
Start: 02/03/20 End: 03/02/22 Due: 03/02/23

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase: N/A Priority: Normal
NCT ID: NCT04262804 Org: User:
Start: 01/13/20 End: 12/31/23 Due: 12/31/24

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Phase: N/A Priority: Normal
NCT ID: NCT04282980 Org: User:
Start: 04/23/20 End: 08/23/22 Due: 08/23/23

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06179069 Org: User:
Start: 01/23/24 End: 07/31/27 Due: 07/31/28

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03551171 Org: User:
Start: 12/19/17 End: 07/10/18 Due: 07/10/19

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Phase: N/A Priority: Normal
NCT ID: NCT04398108 Org: User:
Start: 08/25/20 End: 04/27/21 Due: 04/27/22

A Study of ZL-1310 in Participants With Selected Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06885281 Org: User:
Start: 05/12/25 End: 06/30/27 Due: 06/30/28

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05866354 Org: User:
Start: 06/16/23 End: 11/02/23 Due: 11/02/24

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT03516071 Org: User:
Start: 05/17/17 End: 07/19/19 Due: 07/19/20

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04392102 Org: User:
Start: 08/04/20 End: 08/11/22 Due: 08/11/23

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Phase: N/A Priority: Normal
NCT ID: NCT03705156 Org: User:
Start: 06/08/17 End: 08/24/24 Due: 08/24/25

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04212221 Org: User:
Start: 04/20/20 End: 04/27/22 Due: 04/27/23

A Trial of ZL-1201 in Subjects With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04257617 Org: User:
Start: 05/11/20 End: 01/19/23 Due: 01/19/24

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03516084 Org: User:
Start: 08/20/18 End: 03/20/20 Due: 03/20/21

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Phase: N/A Priority: Normal
NCT ID: NCT04633122 Org: User:
Start: 11/25/20 End: 07/20/22 Due: 07/20/23

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05263986 Org: User:
Start: 05/30/22 End: 10/31/23 Due: 10/31/24

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04653038 Org: User:
Start: 10/29/20 End: 03/02/22 Due: 03/02/23